Pharmaceutical

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Peritoneal Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Peritoneal Cancer.

Apr 19, 2024 - 00:00
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Peritoneal Cancer.
Read the original article

Tags:

Previous Article

Solving antibiotic and pesticide resistance with infectious worms

Next Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Solid Tumor: Likelihood ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Listen: Physicians have a moral and professional obligation to get into ‘good trouble’

Opinion: Listen: Physicians have a moral and profession...

Jun 14, 2023

Medicines Patent Pool broadens access to generic injectable PrEP for HIV

Medicines Patent Pool broadens access to generic inject...

Mar 31, 2023

Black people are more likely to be physically restrained in emergency rooms, study finds

Black people are more likely to be physically restraine...

Sep 26, 2023